Link to this page
Biological and Environmental Research Ontology
| Preferred Name | Zafirlukast | |
| Synonyms |
|
|
| Definitions |
A tolyl compound and leukotriene receptor antagonist (LTRA), with anti-asthmatic and potential capsular contracture-preventing activities. Upon administration, zafirlukast selectively and competitively binds to and blocks the cysteinyl leukotriene 1 receptor (CYSLTR1), thereby preventing the potent pro-inflammatory mediators leukotriene C4, D4 and E4 from binding. This prevents leukotriene-mediated actions, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, inflammation, capillary permeability and bronchoconstriction. In addition, zafirlukast may decrease collagen deposition, fibrosis, and capsular thickness after implantation, thereby preventing scar tissue. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C47785 |
|
| ALT_DEFINITION |
A drug used to prevent and treat symptoms of asthma. It blocks substances that cause inflammation in the lungs. It is a type of antiasthmatic agent and a leukotriene receptor antagonist.
|
|
| CAS_Registry |
107753-78-6
|
|
| CHEBI_ID |
CHEBI:10100
|
|
| Chemical_Formula |
C31H33N3O6S
|
|
| code |
C47785
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A tolyl compound and leukotriene receptor antagonist (LTRA), with anti-asthmatic and potential capsular contracture-preventing activities. Upon administration, zafirlukast selectively and competitively binds to and blocks the cysteinyl leukotriene 1 receptor (CYSLTR1), thereby preventing the potent pro-inflammatory mediators leukotriene C4, D4 and E4 from binding. This prevents leukotriene-mediated actions, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, inflammation, capillary permeability and bronchoconstriction. In addition, zafirlukast may decrease collagen deposition, fibrosis, and capsular thickness after implantation, thereby preventing scar tissue.
|
|
| Display_Name |
Zafirlukast
|
|
| FDA_UNII_Code |
XZ629S5L50
|
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C176424 |
|
| label |
Zafirlukast
|
|
| Legacy Concept Name |
Zafirlukast
|
|
| NCI_Drug_Dictionary_ID |
790373
|
|
| PDQ_Closed_Trial_Search_ID |
790373
|
|
| PDQ_Open_Trial_Search_ID |
790373
|
|
| Preferred_Name |
Zafirlukast
|
|
| prefixIRI |
NCIT:C47785
|
|
| prefLabel |
Zafirlukast
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0378466
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |